Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Mycophenolate mofetil (MMF) in systemic sclerosis-associated interstitial lung disease (SSc-ILD)


  • Please log in to reply
1 reply to this topic

#1 Jeannie McClelland

Jeannie McClelland

    Senior Gold Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 1,706 posts
  • Location:in the Rocky Mountains of the USA

Posted 28 July 2010 - 01:26 AM

Mycophenolate mofetil (MMF) in systemic sclerosis-associated interstitial lung disease (SSc-ILD). In this retrospective study, we reviewed the medical files of 10 patients with SSc-ILD and found that MMF stabilizes lung function of SSc-ILD after 12 months of treatment. Athanasios Koutroumpas. (SpringerLink) Clinical Rheumatology. 06/09/10. (Also see: Cellcept and Pulmonary Fibrosis Treatments)

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Jeannie McClelland
(Retired) ISN Director of Support Services
(Retired) ISN Sclero Forums Manager
(Retired) ISN Blog Manager
(Retired) ISN Assistant News Guide
(Retired) ISN Artist
International Scleroderma Network

#2 janey

janey

    Platinum Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 2,118 posts
  • Location:New Mexico

Posted 29 July 2010 - 01:38 PM

This is interesting. I'd like to see them review more than 10 patients. I've been on cellcept for more than 3 years and after a year, my forced vital capacity (FVC)increased from 45 to 60 and has remained stable. My diffusing capacity (DLCO) was at 49 in March 07 and it has stayed between 45 and 50, so no significant increase. So my personal results seem to echo the results of this study. Everything has been stable for about 2 years now. I'll take it.
Janey Willis
ISN Support Specialist
(Retired) ISN Assistant Webmaster
(Retired) ISN News Director
(Retired) ISN Technical Writer for Training Manuals
International Scleroderma Network (ISN)